What question did this study set out to answer?

This research aims to determine the long-term impact of lovastatin on the quality of life in individuals at risk of coronary heart disease.

June 23, 1993JAMA

HMG CoA reductase inhibitors and quality of life

View Full Paper

Ask AI

Bookmark

Why the study?

Does lovastatin prevent coronary heart disease and impact quality of life in asymptomatic persons with mild to moderate cholesterol elevations?

Population

6605 participants without clinical evidence of coronary heart disease, including men aged 45 to 73 years and…

Comparison

Lovastatin vs Placebo

Design

Editorial, randomized, double-blind

Follow-up

minimum of 5 years

Authors

JDJohn R. DownsUniversity of North Texas

Discussion

Member takes

Implication

This letter highlights the importance of assessing the long-term impact of cholesterol-lowering drug treatment on patient quality of life in the ongoing AFCAPS primary prevention trial.

Key Points

This research aims to determine the long-term impact of lovastatin on the quality of life in individuals at risk of coronary heart disease.
Randomized, double-blind, placebo-controlled trial
Involved 6605 participants aged 45-73 years
Follow-up period of a minimum of 5 years for coronary heart disease events
Assessing quality of life associated with long-term cholesterol-lowering drug treatment in asymptomatic individuals
Evaluating prevention of coronary heart disease events among participants
Comparative analysis between treatment and placebo groups

Structured PICO

Does lovastatin prevent coronary heart disease and impact quality of life in asymptomatic persons with mild to moderate cholesterol elevations?

Population

6605 participants without clinical evidence of coronary heart disease, including men aged 45 to 73 years and women aged 55 to 73 years, with mild to moderate elevations of total and low-density lipoprotein cholesterol and low high-density lipoprotein cholesterol levels

Intervention

Lovastatin

Comparator

Placebo

Outcome

Total coronary heart disease eventshard clinical

This letter highlights the importance of assessing the long-term impact of cholesterol-lowering drug treatment on patient quality of life in the ongoing AFCAPS primary prevention trial.

Cite This Study

John R. Downs (1993) studied this question.

synapsesocial.com/papers/6a731dad08591dcdd92b30d7 https://doi.org/10.1001/jama.269.24.3107

Topics

Statin therapy

View Full Paper

Ask AI

Bookmark

Implication

This letter highlights the importance of assessing the long-term impact of cholesterol-lowering drug treatment on patient quality of life in the ongoing AFCAPS primary prevention trial.

HMG CoA reductase inhibitors and quality of life

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

HMG CoA reductase inhibitors and quality of life

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider